IBIS - An immune-therapeutic salvage strategy for ‘functional’ high-risk (FHR) multiple myeloma incorporating Iberdomide, Isatuximab, and Dexamethasone (Iber-IsaDex) – the IBIS study

Project: Research

Project Details

StatusActive
Effective start/end date16/08/22 → 1/07/26

Keywords

  • Clinical trial
  • multiple myeloma
  • immune therapy
  • IBIS